₹ 2.0 Cr
Volume transacted
3.0 K
stocks traded
Last Updated time: 26 Jul 09:04 AM
Sanofi India Ltd
NSE: SANOFI
DPS
₹ 167
Last updated : FY 2023
The Dividend per Share of Sanofi India Ltd is ₹ 167 as of 2023 .a1#The Dividend Payout of Sanofi India Ltd changed from 209.58 % to 63.68 % over 5 quarters. This represents a CAGR of -61.44% a1#The Latest Trading Price of Sanofi India Ltd is ₹ 6710 as of 25 Jul 15:30 .a1#The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 .a1#The Revenue of Sanofi India Ltd changed from ₹ 780.1 crore to ₹ 738.9 crore over 5 quarters. This represents a CAGR of -4.25% a1#The EBITDA of Sanofi India Ltd changed from ₹ 273.5 crore to ₹ 198.7 crore over 5 quarters. This represents a CAGR of -22.56% a1#The Net Pr of Sanofi India Ltd changed from ₹ 190.4 crore to ₹ 136.6 crore over 5 quarters. This represents a CAGR of -23.33% a1#
Open Demat Account
Enter your mobile no. to continue
+91
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
Market Cap
₹ 15,453 Cr
EPS
₹ 246.3
P/E Ratio (TTM) *
27.2
P/B Ratio (TTM) *
15.2
DTE *
0.0
ROE *
59.4
ROCE *
79.6
Dividend Yield *
2.07
DPS *
167
Dividend Payout *
63.68
Ann.Dividend % *
1670
* All values are consolidated
Last Updated time: 26 Jul 09:04 AM
* All values are consolidated
Last Updated time: 26 Jul 09:04 AM
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Period | |
---|---|
December 2019 | 210 |
December 2020 | 176 |
December 2021 | 119 |
December 2022 | 211 |
December 2023 | 64 |
* All values are a in %
Dividend Yield is a financial ratio that shows the annual dividend income relative to the market price of a share. It is calculated by dividing the dividend per share by the current market price per share, expressed as a percentage.
* All values are in %
Sanofi India Ltd
NSE: SANOFI
PRICE
₹ 6710.15
151.95 (2.32%)
Last updated : 25 Jul 15:30
Strength
2
S
Weakness
1
W
Opportunity
0
O
Threats
1
T
Revenue
Profitability
Affordability
Liquidity
Dividend
A dividend is paid on common stock when a company has accumulated substantial profits over years, often seen as excess cash that doesn't need immediate use.
A quarterly dividend is paid to preferred stock owners, typically accumulating a fixed amount, and is earned on shares that function more like bonds.
Companies declare interim dividends before final full-year accounts are prepared, specifically in India, during the financial year from April to March of the following year.
A final dividend is issued after the year's accounts have been compiled. Aside from this, the following list highlights the most prevalent sorts of dividends:
Sanofi India Ltd
NSE: SANOFI
MARKETCAP
₹ 18579 crore
Last updated : December 2023
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.
Period | |
---|---|
Jun '23 | 780 |
Sep '23 | 722 |
Dec '23 | 726 |
Mar '23 | 706 |
Jun '24 | 739 |
* All values are a in ₹crore
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Period | |
---|---|
Jun '23 | 274 |
Sep '23 | 194 |
Dec '23 | 220 |
Mar '23 | 199 |
Jun '24 | 199 |
* All values are a in ₹crore
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue
Period | |
---|---|
Jun '23 | 190 |
Sep '23 | 123 |
Dec '23 | 152 |
Mar '23 | 138 |
Jun '24 | 137 |
* All values are a in ₹crore
Sanofi India Limited, (Previously known as Aventis Pharma Limited), is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market. The Company offers a wide array of medicines for therapy areas such as Diabetes (both insulins, and oral medications), Cardiology, Thrombosis, Epilepsy, Allergies, Infections, Vitamins, Central Nervous System and Antihistamines. The products manufactured by the Company are distributed in India and exported to many developed as well as developing countries, including Germany, Australia, UK, Russia and Italy. Sanofi India's products viz. Lantus, Combiflam, Amaryl and Allegra feature in the top 100 pharmaceutical brands in India. The Company has its own manufacturing facility at Goa and Ankleshwar, Gujarat. It sells products through independent distributors primarily in India. Sanofi, one of the world's leading pharmaceutical companies, and its 100% subsidiary, Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.37% of its paid-up share capital. The Company was incorporated in May 1956 under the name 'Hoechst Fedco Pharma Private Limited'. Over the years, the name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited, Aventis Pharma Limited and Sanofi India Limited. During the year 1997-98, the Joint Venture Company, Chiron Behring Vaccines Pvt Ltd started to manufacture anti-rabbies vaccine 'Rabipur'. Roussel India Ltd was amalgamated with the Company with effect from April 1, 1997 and Hoechst Nepal (Pvt) Ltd, a subsidiary Company in Nepal was wound up during the year. During the year 1999-2000, Aventis launched anti-diabetic Amaryl broad spectrum anti-infective Tavanic and line extension of anti-hypertensive Cardace H. In the year 2001, Rhone-Poulenc Rorer (India) Pvt Ltd was amalgamated with the company. The company name was changed from Hoechst Marion Roussel Ltd to Aventis Pharma Ltd with effect from July 11 2001. In July 2003. the company launched Lantus, the world's first and only once a day insulin and in December 2003, Actonel, designed for the treatment of osteoporosis was launched. In the year 2004, the company came under the control of Sanofi-Synthelabo, now called sanofi-aventis which acquired indirect control 50.1% of the company's paid-up share capital. In the year 2006, the company completed the project for setting up additional facilities for manufacturing Combiflam Tablets in Ankleshwar, Gujarat. In the year 2007, the company launched Cardace H 10 mg as a comprehensive cardiovascular treatment option in hypertension at risk patients. In May 2007, the company launched a line extension, Amaryl M. A new granulation train dedicated for production of Combiflam tablets was installed in Ankleshwar. This product which was being manufactured partly in a toll manufacturing site is now planned to be manufactured entirely in Ankleshwar. In April 2008, the company launched a new prefilled diaposable insulin pen, SoloStar for use with the 24-hour insulin Lantus. This disposable insulin pen is to be used for the treatment of hyperglycemia in people with type 1 or type 2 diabetes. On 13 December 2010, Aventis Pharma Ltd announced that it has agreed with its joint venture partner Novartis Vaccines & Diagnosics Inc. to sell its 49% shareholding in Chiron Behring Vaccines Private Limited (CBVPL) to Novartis Pharma AG and exit the joint venture. The purchase price agreed to be paid is US Dollars 22.399 million. Simultaneously, Aventis Pharma has agreed to continue to provide certain utilities and services to the Ankleshwar plant of CBVPL for a period of three years from the date of closing on mutually terms. CBVPL manufactures the anti-rabies vaccine Rabipur at its plant in Ankleshwar, which was until February 2009 distributed in India by Aventis Pharma and is presently distributed by Novartis Healthcare Private Limited. On 27 December 2010, Aventis Pharma Ltd announced that it has completed the sale of its 49% shareholding in Chiron Behring Vaccines Private Limited to Novartis Pharma AG. The company received sale consideration of Rs 100.75 crore (equivalent to US Dollars 22.399 million). On 24 August 2011, Aventis Pharma Limited (part of the Sanofi Group) announced that it has entered into a definitive agreement to acquire Universal Medicare Private Limited's business of marketing and distribution of branded nutraceutical formulations in India. Also, approximately 750 commercial employees will transition to Aventis Pharma Ltd. The transaction has been approved by the Boards of Directors of both companies. It is expected to close in the fourth quarter of 2011, subject to certain conditions precedent. Universal Medicare, (headquartered in Mumbai, India) manufactures, markets and distributes branded nutraceutical formulations in India through their sales and marketing infrastructure. With this acquisition, Aventis Pharma will advance its sustainable growth strategy in India and facilitate the creation of a consumer healthcare and wellness platform. The Registrar of Companies approved the company's change of name from Aventis Pharma Limited to Sanofi India Limited with effect from 11 May 2012. The shareholders of the company had earlier approved the name change at the Annual General Meeting held on 3 May 2012. The decision to change the name of the Group's listed entity in India comes a year after the name of the parent company was changed globally from sanofi-aventis to Sanofi in May 2011. On 9 October 2012, Sanofi India Limited announced the launch of AllStar, its first indigenously manufactured re-usable insulin pen. On 14 February 2013, Sanofi India Limited announced the launch of Combiflam Plus, a targeted, fast and effective solution for headaches, which is also gentle on the stomach. A line extension of one of Sanofi India's flagship brand Combiflam, the launch of this new product marks the company's foray into the OTC headache segment in India. On 11 November 2014, Sanofi India announced that its Board of Directors has approved of the company selling its commercial premises, being five floors and corresponding car-parking spaces in the building known as Hoechst House situated at Nariman Point, Mumbai to Bright Star Investments Private Limited and its Group companies for a total consideration of Rs 134.25 crore. On 21 July 2015, Sanofi India announced that its Board of Directors has approved of the company selling its commercial property, being land and building at Andheri, Mumbai for a consideration of Rs 111 crore. The transaction is expected to be completed in the quarter ending 30 September 2015. In August 2017, the first OTC extension of the iconic brand Combiflam was launched in the topical pain care space with the name Combiflam Icy Hot. 12 February 2018, Sanofi India announced the launch of its new insulin product Toujeo. Toujeo is a once-daily, long-acting basal analog insulin that improves glycemic control in adults with type 1 and type 2 diabetes. In 2019, Sanofi launched Combiflam Plus (Paracetamol and Caffeine combination). Besides, two new brands were launched, DePura by Sanofi Cal. On 29th May 2020, the Company closed the transaction of slump sale and transfer of its Ankleshwar manufacturing facility to Zentiva Private Limited. During the year 2021-22, the Company's Nutraceuticals business, was sold as a going concern basis to Universal Nutriscience Private Limited through Slump Sale for a consideration of Rs. 587 Crore, effective on September 30, 2021. In 2021, a unique Toustarr pen, dedicated cartridge system device was launched.
Sanofi India Ltd spurts 1.9%, rises for fifth straight session
Sanofi India Ltd gained for a fifth straight session today. The stock is quoting at Rs 668...
Read more
25 Jul 202413:00
Sanofi India Ltd drops for fifth straight session
Sanofi India Ltd fell for a fifth straight session today. The stock is quoting at Rs 6438....
Read more
09 Jul 202413:36
Sanofi India to conduct board meeting
Sanofi India will hold a meeting of the Board of Directors of the Company on 26 July 2024....
Read more
08 Jul 202417:07
Sanofi India Ltd leads losers in 'A' group
Caplin Point Laboratories Ltd, Gravita India Ltd, AAVAS Financiers Ltd and Shivalik Bimeta...
Read more
13 Jun 202415:00
Sanofi India Ltd eases for fifth straight session
Sanofi India Ltd dropped for a fifth straight session today. The stock is quoting at Rs 84...
Read more
30 May 202413:35
Sanofi India Ltd spurts 1.3%, up for fifth straight session
Sanofi India Ltd gained for a fifth straight session today. The stock is quoting at Rs 898...
Read more
21 May 202413:00
FAQs for dividends of Sanofi India Ltd
What is the current market price of Sanofi India Ltd Ltd as of July 26, 2024?
What dividend did Sanofi India Ltd declare in the last fiscal year?
What is the most recent dividend declared by Sanofi India Ltd?
How many times has Sanofi India Ltd declared dividends in the current fiscal year
How many times did Sanofi India Ltd declare dividends in the previous fiscal year?
Unlimited trading at just
Rs. 199